Formoterol fumarate is a new beta 2-adrenergic agonist with a long lasting effect. The bronchospasmolytic effect of 12 micrograms of formoterol was compared with that of 200 micrograms of albuterol (salbutamol) in a single-center, double-blind, randomized within-patient study. The drugs were given as aerosols by MDI to 16 patients with nocturnal asthma in a stable phase. The inhalations were gi...

BACKGROUND Divergent strategies have emerged for the management of severe asthma. One strategy utilises high and fixed doses of maintenance treatment, usually inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), supplemented by a short-acting β2-agonist (SABA) as needed. Alternatively, budesonide/formoterol is used as both maintenance and reliever therapy. The latter is superior to fixed-d...

INTRODUCTION The objective of this study was to estimate the relative efficacy and safety of fixed-dose combination aclidinium/formoterol 400/12 μg twice daily compared to tiotropium 18 μg once daily in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). METHODS A systematic literature review performed in March 2014, using a predefined search strategy in MEDLI...

Methods Ninety-three patients with moderate to severe uncontrolled asthma from rural outpatient clinics were included in this study. 54 women and 39 men, their age ranged from 19 to 61 years (average 35.6±4.53). None of them has ever used the combination of budesonide and formoterol before. Every subject underwent a 3-month treatment with budesonide/formoterol, daily doses of budesonide ranged ...

in asthma The study by Wolfe et al certainly does not support our claim that serious asthma exacerbations are more frequent in patients receiving formoterol 24 μg twice daily than in those receiving 12 μg twice daily, or placebo. Actually, this statement should have been based on the review by Mann et al, that assessed data from three prospective, randomised, placebo-controlled and double-blind...

BACKGROUND Combining two long-acting bronchodilators with complementary mechanisms of action may provide treatment benefits to patients with chronic obstructive pulmonary disease (COPD) that are greater than those derived from either treatment alone. The efficacy and safety of a fixed-dose combination (FDC) of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol fumarate, a l...

BACKGROUND AND PURPOSE Long-acting beta2-agonists (LABAs) have proved to be useful in the management of asthma and prevention of exacerbations. LABAs can modulate inflammatory and repair processes in the airways of individuals affected by many respiratory disorders. This study assessed the effects of LABAs on the release of inflammatory mediators by bronchial epithelia. METHODS The effects of...

STUDY OBJECTIVES Airway neutrophil levels are increased in patients with severe asthma and during asthma exacerbations. Long-acting beta2-agonists (LABAs), such as formoterol, reduce the number of asthma exacerbations. While beta2-agonists may affect neutrophil function in vitro, it is uncertain whether they have effects on neutrophilic inflammation in asthmatic patients in vivo. DESIGN In a ...

This randomized, double-blind, placebo-controlled, crossover study was designed to investigate the effects of the long-acting beta2-adrenoreceptor agonist formoterol fumarate in 12 current or exsmokers having chronic obstructive pulmonary disease, with a mean forced expiratory volume in one second (FEV1) 47% of predicted, poorly reversible (5.1% pred) after terbutaline sulphate inhalation. Afte...